The most expensive drug category for nonfederal hospitals in 2024 were antineoplastic targeted agents, according to a study published in the American Journal of Health-System Pharmacy.  The report, ...

According to the results of a new study in the New England Journal of Medicine, 92% of patients who took this drug were cancer-free after two years.

Shares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination ...